Aratana Therapeutics receives FDA approval of canine appetite stimulus
Aratana Therapeutics Inc. has received approval from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) of Entyce—a first-of-its-kind ghrelin receptor agonist that stimulates appetite in dogs—according to a company release.
Entyce, a new chemical entity, works by mimicking the hunger hormone ghrelin to stimulate appetite. The prescription medication is a flavored liquid that is administered orally.
“Nearly 10 million dogs are diagnosed with inappetence each year and we believe Entyce will fulfill a significant unmet need to stimulate appetite in dogs,” says Steven St. Peter, MD, president and chief executive officer of Aratana Therapeutics, in the release. Aratana is reportedly planning a February 2017 commercial launch of Entyce in order to coincide with the North American Veterinary Conference.